Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... JUPITER, Fla. , Feb. 26, 2015 /PRNewswire/ ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... will report its financial results for year ending ... March 11, 2015 and will host a conference ...
(Date:2/26/2015)... Feb. 26, 2015 Ceres, Inc . ... in Oracle PartnerNetwork. In attaining Gold Level membership, Ceres ... establish Oracle-related knowledge in delivering Ceres, Persephone genome visualization ... customers. Originally developed for in-house use by ... in and out of massive amounts of genetic data, ...
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  Epic Sciences ... , Ph.D. will present at the 35th Annual Cowen ... a.m. EST in the MIT Room, 3rd Floor. The ... Place Hotel in Boston, Mass. Epic is developing ... detection of genomic and proteomic changes that occur during ...
(Date:2/26/2015)... Feb. 26, 2015  Spark Therapeutics (NASDAQ: ONCE ... will participate in the Cowen and Company Health Care ... Eastern, at the Boston Marriott Copley Place. ... presentation from the Cowen conference, please visit the "Upcoming ... the Spark Therapeutics website at www.sparktx.com .  A ...
Breaking Biology Technology:Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2
... SAN FRANCISCO, Calif., April 8, 2008 Raven,biotechnologies, ... discovery,and development of monoclonal antibody therapeutics (MAbs) for ... agreement with Monogram,Biosciences, Inc., under which Monogram will ... VeraTag(TM) technology for diagnosis,of cancer., "Raven,s extensive ...
... Flexibility, Expanding Physicians ... the Treatment of Prostate Cancer, SUNNYVALE, Calif., April ... global leader in the field of radiosurgery,announced today that ... the,International Journal of Radiation Oncology*Biology*Physics -- also known,as the ...
... The Board of Molecular Vision today,announces that discussions ... have now ceased. Acrongenomics has been unable to,complete ... the Board of,Molecular Vision believes that the best ... discussions to a conclusion. Acrongenomics remains a,significant shareholder ...
Cached Biology Technology:Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies 2CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal 2CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal 3CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal 4
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... food choices based on television advertising results in a very ... content of food choices influenced by television to nutritional guidelines ... the American Dietetic Association . Investigators found that ... 25 times the recommended servings of sugars and 20 times ...
... have identified a previously unknown kinase that regulates cell proliferation, ... the progression or metastasis of cancer cells. The ... Edition of the Proceedings of the National Academy of ... at the UCSD School of Medicine and the Moores Cancer ...
... 31, 2010) -- A compound found in sunless tanning spray ... results published by plastic surgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical ... University in Ithaca, N.Y., where the novel compound was developed. ... National Academy of Sciences show that a sticky gel ...
Cached Biology News:TV food advertisements promote imbalanced diets 2Newly discovered kinase regulates cytoskeleton, and perhaps holds key to how cancer cells spread 2Sugary band-aid may help heal post-operative tissue 2
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: